| Name | Title | Contact Details |
|---|
AIC-Isreal is a Memphis, TN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
MEDHOST is a provider of market-leading enterprise, departmental and healthcare engagement solutions to more than 1,100 healthcare facilities. Our integrated product portfolio includes intuitive, cloud-based solutions, including YourCareEverywhere, a robust health and wellness consumer engagement platform. Our broad offering of hosting, outsourcing, marketing and consulting services are changing how clinicians and hospital leaders work and collaborate, while generating notable operational improvements. MEDHOST delivers value by enabling hospitals of all types and all sizes to better manage the business of healthcare across the care continuum while meeting evolving regulatory requirements.
Steelcraft is a Millbury, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Nucletron Corp. is a Columbia, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded in 2011, Sight Sciences develops and commercializes intelligently designed and engineered products that target the underlying causes of the world`s most prevalent eye diseases. The company`s surgical glaucoma product portfolio features the OMNI Surgical System, a dually indicated MIGS device that facilitates the performance of both ab interno trabeculotomy and transluminal viscoelastic delivery. Using proprietary multi-modal functionality, OMNI allows surgeons to target all three sources of resistance in the conventional outflow pathway (trabecular meshwork, Schlemm`s canal and collector channels) with a single device and single corneal incision. The company`s non-surgical dry eye product portfolio consists of the TearCare for ophthalmologists and optometrists. TearCare is a software-controlled, wearable, therapeutic eyelid technology designed to melt and clear obstructions of the meibomian glands within the eyelids. Leveraging the full functionality of the blinking eye, proprietary SmartLid™ technology is designed to conform to all eyelid anatomies and achieve therapeutic meibum melting temperatures at the tarsal conjunctiva thereby clearing meibomian gland obstructions while sparing the cornea. Improved meibum production results in a higher quality lipid layer and higher quality tears.